Search

Your search keyword '"Donoghue, Mark"' showing total 648 results

Search Constraints

Start Over You searched for: Author "Donoghue, Mark" Remove constraint Author: "Donoghue, Mark"
648 results on '"Donoghue, Mark"'

Search Results

1. Automated real-world data integration improves cancer outcome prediction

2. Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy

4. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors

6. Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC

7. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade

8. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

9. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer

10. Ordered and deterministic cancer genome evolution after p53 loss

11. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer

13. Anatomic position determines oncogenic specificity in melanoma

14. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

16. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

17. AKT mutant allele-specific activation dictates pharmacologic sensitivities

18. Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer

19. Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome

21. Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer

22. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

23. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor

27. Supplementary Table S3 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

28. Supplementary Figure S15 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

29. Data from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

30. Homologous recombination deficiency and tumor suppressor heterozygosity mediate resistance to front-line therapy in breast cancer

31. Immune checkpoint inhibitor response in sarcomas associates with immune infiltrates and increased expression of transposable elements and viral response pathways

32. Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies

33. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

45. Tumour lineage shapes BRCA-mediated phenotypes

46. Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer

47. Supplementary Table S3 from Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets

48. Supplementary Figure S3 from Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets

49. Data from Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets

50. Supplementary Figure S6 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Catalog

Books, media, physical & digital resources